文献速递消化系统肿瘤

S-IROX(替吉奥、伊立替康和奥沙利铂联合治疗)在晚期胰腺癌患者中的安全性和疗效:一项多中心1b期剂量递增和剂量扩展临床试验

Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial.
PubMed 文献 · Eur J Cancer · 2022-08-12

这项1b期试验评估S-IROX作为晚期胰腺癌一线化疗的毒性和疗效。45例可分析患者中,常规缓解率为51.1%(95%CI 35.8-66.3%),中位无进展生存期6.9个月(95%CI 5.1-8.8个月),中位总生存期15.8个月(95%CI 9.8-20.8个月)。结论认为该方案在日本晚期胰腺癌患者中显示出有前景的疗效且毒性可控。

要点

  • 45例可分析患者的常规缓解率为51.1%(95%CI 35.8-66.3%)。
  • 中位无进展生存期6.9个月(95%CI 5.1-8.8个月),中位总生存期15.8个月(95%CI 9.8-20.8个月)。
  • 常见不良事件包括中性粒细胞减少、肝酶升高、腹泻和恶心。

核心结论

  • S-IROX方案在日本晚期胰腺癌患者中显示出有前景的疗效且毒性可控。
  • 一项比较S-IROX、mFOLFIRINOX和吉西他滨联合白蛋白结合型紫杉醇的随机2/3期试验正在进行中(jRCTs031190009)。

研究设计与样本

  • 这项1b期试验评估S-IROX作为晚期胰腺癌一线化疗的毒性和疗效。
  • 纳入20-75岁、美国东部肿瘤协作组体能状态评分为0或1的晚期胰腺癌患者。
  • 剂量递增:替吉奥60或80 mg m2·day第1-7天,奥沙利铂85 mg/m2每两周固定剂量,伊立替康150、165或180 mg/m2每两周一次。
  • 剂量递增队列采用3+3设计确定最大耐受剂量并探索推荐剂量,另加剂量扩展队列进一步评估安全性和疗效。
  • 试验注册于UMIN-CTR(UMIN000012054)。

主要发现

  • 约47例患者入组,其中45例可分析。
  • 最大耐受剂量未确定,但基于各剂量水平数据回顾,推荐剂量确定为剂量水平1。
  • 45例患者中,常规缓解率为51.1%(95%CI 35.8-66.3%)。
  • 中位无进展生存期为6.9个月(95%CI 5.1-8.8个月),中位总生存期为15.8个月(95%CI 9.8-20.8个月)。
  • 常见不良事件包括中性粒细胞减少、肝酶升高、腹泻和恶心。

关键数值与推荐

  • 推荐剂量确定为剂量水平1(基于各剂量水平数据回顾)。
  • 常规缓解率51.1%(95%CI 35.8-66.3%)。
  • 中位无进展生存期6.9个月(95%CI 5.1-8.8个月)。
  • 中位总生存期15.8个月(95%CI 9.8-20.8个月)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为S-IROX方案在日本晚期胰腺癌患者中显示出有前景的疗效且毒性可控。

局限性

  • 最大耐受剂量未确定。
  • 原文报告约47例患者入组,其中45例可分析。
  • 原文结论指出一项随机2/3期试验正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This phase 1b trial evaluated the toxicity and efficacy of S-1, irinotecan, and oxaliplatin combination therapy (S-IROX) as first-line chemotherapy in patients with advanced pancreatic cancer (APC). METHODS: Patients aged 20-75 years with APC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible to receive escalating doses of S-1 (60 or 80 mg m2·day) on days 1-7, fixed doses of oxaliplatin (85 mg/m2) biweekly, and escalating doses of irinotecan (150, 165, or 180 mg/m2) once every 2 weeks. In the dose-escalation cohort, a 3 + 3 design was used to determine the maximum-tolerated dose (MTD) and explore the recommended dose (RD). A dose-expansion cohort was added to further evaluate the safety and efficacy of the combination. This trial was registered at UMIN-CTR (UMIN000012054). RESULTS: Approximately 47 patients were enrolled, of whom 45 were eligible for the analysis. The MTD was not determined, but the RD was determined to be dose level 1 based on a review of data from each level. Among the 45 patients, the ORR was 51.1% [95% confidence interval (CI), 35.8-66.3%]. The median progression-free survival and median overall survival was 6.9 months (95% CI, 5.1-8.8 months) and 15.8 months (95% CI, 9.8-20.8 months), respectively. Common adverse events included neutropenia, elevated liver enzyme levels, diarrhoea, and nausea. CONCLUSIONS: The S-IROX regimen showed promising efficacy with manageable toxicities in Japanese patients with APC. A randomised phase 2/3 trial comparing S-IROX, mFOLFIRINOX, and gemcitabine plus nab-paclitaxel is currently ongoing (jRCTs031190009).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ohba A, Ueno H, Shiba S, et al. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer. 2022. PMID: 35970035. doi:10.1016/j.ejca.2022.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。